Top

Reactions Weekly

Published in:

01-08-2023 | Dronabinol | Case report

Dronabinol

Hyperlipasemia and cannabinoid hyperemesis syndrome: 2 case reports

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Richet E, et al. [Use of dronabinol in the treatment of resistant neuropathic pain: Feedback from patients followed in a multidisciplinary pain center]. [French]. Annales Pharmaceutiques Francaises 81 : 720-729, No. 4, Jan 2023. Available from: URL: http://doi.org/10.1016/j.pharma.2022.12.005 [French; summarised from a translation]

Title: Dronabinol
Hyperlipasemia and cannabinoid hyperemesis syndrome: 2 case reports
Publication date: 01-08-2023
Publisher: Springer International Publishing
Keywords: Dronabinol
Cannabinoid
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-44294-x

At a glance: The STEP trials

Springer Medicine

Dronabinol

Hyperlipasemia and cannabinoid hyperemesis syndrome: 2 case reports

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Cefotaxime

Multiple drugs

Mepolizumab/prednisolone

Doxorubicin

Carbamazepine/imatinib

SSRI treatment increases risk of rhabdomyolysis